Obstructive sleep apnea syndrome (OSAS) is a condition characterized with the occurrence during sleep of apneas or hypopneas associated with upper airway collapse .
The association between high blood pressure and OSA is common. The main mechanism that explains this association is stimulation of sympathetic nervous system during apneas. Alongside this mechanism, the activation of renin-angiotensin-aldosterone system due to hypoxemia, that increase in preload and afterload linked to negative intrathoracic pressure and finally oxidative stress with dysfunction endothelial and other pathophysiological mechanisms that link arterial hypertension to OSA   . From an epidemiological point of view, approximately 50% of patients with OSA are hypertensive .
Arterial hypertension (hypertension) associated with obstructive sleep apnea syndrome exhibits several characteristics including high prevalence, diastolic and nocturnal predominance, non-dipper status and resistance to antihypertensive therapy .
Treatment of OSAS with continuous positive airway pressure (CPAP) may have beneficial effect on hypertension control when the patient is observant  .
The objective of this work was to relate the benefit of screening and treatment of severe OSA to resistant hypertension. The patient’s that is free and inform his consent has been obtained.
This is a 50 year old patient with a well known hypertension since 2006 and we have been following him since 2013. He was treated with Perindopril 10 mg + Amlodipine 10 mg: 1 tablet per day for several years stable. After discovering his diabetes in 2015, with high blood pressure it was more difficult to control. It was added to his treatment Spironolactone 50 mg + Altizide 15 mg: 1 tablet per day. From June 2019, we added Rilménidine 2 mg per day to it.
The above treatment seemed to be effective. Several other therapeutic combinations had been tried without success, in particular the combination of Amlodipine 10 mg + Valsartan 160 mg, Irbesartan 300 mg + hydrochlorothiazide 25 mg.
Type 2 diabetes was treated with: Metformin 850 mg daily, in combination with Glimépiride 2 mg per day.
He was also treated for dyslipidemia with Rosuvastatin 20 mg per day.
After several months with this same treatment, his hypertension was not balanced.
Interviewing the patient at night while snoring, morning physical asthenia associated with episodes of daytime sleepiness, and erectile dysfunction.
The physical examination noted android-type obesity (abdominal circumference = 102 cm), weight = 79 kg; height = 168 cm; BMI = 27.99 kg/m2; Blood pressure = 180/110 mmHg.
The sounds of the heart was regular, the peripheral pulses was well perceived. The rest of the medical checkup was normal.
Biological medical test discovered: Blood sugar = 0.9 g/l; Glycated hemoglobin = 6.4%; Hemoglobin = 17.2 mg/dl; creatinine = 7.6 mg/l with clearance = 129 ml/min; dyslipidemia with LDL = 2.18 g/l, Total cholesterol = 1093 g/l, HDL = 0.55 g/l; triglycerides = 0.95 g/l. CRP = 31.4 mg/L Blood ionogram was normal. Micro albuminuria was found (240 mg/l).
The EKG showed a steady sinus rhythm at 70 beats per min; the layout was normal.
The chest x-ray was normal.
The echocardiogram was normal.
Ambulatory Blood Pressure Measurement (ABPM) showed unbalanced arterial hypertension with 24 hour means BP = 167/113 mmHg, that shows the patient is not dipper (Figure 1).
Figure 1. Ambulatory BP measurement, the graph indicates unbalanced hypertension with non-dipper status.
Tensional Self-Monitoring (TMA) was also in favor of uncontrolled arterial hypertenion (means BP = 180/110 mmHg).
In Totality, it is a resistant arterial hypertension in a patient with a high cardiovascular risk.
He was not administering any medication that could increase blood pressure. In this research for a secondary cause therefore turns to an obstructive sleeping apnea syndrome questioning.
Ventilatory polygraphy shows a severe obstructive apnea syndrome with (overall IAH at 56.6/H; RDI = 58.6) without positional character. The conclusion is that curves are presented in the appendix (Figure 2, Figure 3).
Figure 2. Ventilatory polygraphy: oximetry and positional data showing a severe nocturnal desaturation (desaturation index per hour = 25.9; average saturation to 96 % for a basal 100% and minimal 79%).
Figure 3. Ventilatory polygraphy: abnormal respiratory events.
Treatment of obstructive apnea syndrome by continuous positive pressure ventilation has been initiated to control high blood pressure. On self-measurement, the means of arterial pressure is 133/80 mmHg from the first month and it has remained stable for 5 months.
In this present work, we reported a clinical case of a patient with resistant hypertension whose cause has been shown to be obstructive sleeping apnea syndrome (OSAS).
Resistant arterial hypertension (hypertension) is defined by blood pressure values above the therapeutic target despite a treatment combining 3 molecules including a diuretic, at maximum well tolerated doses. Its association with obstructive sleeping apnea (OSA) sleep is common. Thus, in a study on hypertension refractory to treatment, Bernard Waeber and François Feihl  showed that OSA was the most frequently found cause (64%). For Damianoet al., The prevalence of OSA reached 83% of hypertensive patients resistant to treatment .
In our clinical case, this is a patient with high cardiovascular risk with age 50, hypertensive and diabetic, with dyslipidemia and obesity. Despite the hygieno-dietetic measures comprising a low-sodium diet, weight loss since he weighed more than 90 kg a few years previously (currently his weight is stable at 79 kg) associated with an anti-hypertensive quadruple therapy at optimal dose, for several months, the blood pressure target was not reached (Figure 1). Faced with this scenario, it was recommended to look for a secondary cause, in particular OSA or drug intake that can influence blood pressure.
The questioning of the patient had made it possible to move towards a sleeping apnea syndrome in front of the notion of bulging associated with daytime sleeplessness. Adjohet al. in Togo  found that 42.2% of patients were sleepy in their study.
Polysomnography is a reference examination for the search for OSA, combining respiratory polygraphy and recording of sleep  . However, ventilatory polygraphy is an alternative to the gold standard. It makes it possible to confirm the presence of apneas and hypopneas, to identify the mechanism (obstructive or central character) and assess the severity. The severity is determined by the index of apnea-hypopnea (IAH) which is a number of apneas and hypopneas per hour. An AHI greater than 30 per hour defines a severe OSA . For clinical case that has been reported, the AHI was 56.6 per hour, qualified as very severe (Figure 3).
Continuous positive airway pressure (CPAP) is the treatment of choice for OSA. The beneficial effect of this device on lowering blood pressure has been demonstrated   . Provided that the patient is observant. In this case of our patient, this beneficial effect was noted from the first months for his or her treatment mean arterial pressure for self-measurement is 133/80 mmHg. It remains stable for more than 5 months.
Resistant hypertension is often seen in overweight or obese patients. This association must systematically search for OSA, treatment of OSA is by CPAP which, when the patient is observant, can significantly lower blood pressure levels and improve the quality of life of patients.
 Baguet, J.-P., Barone-Rochette, G. and Pépin, J.-L. (2009) Syndrome d’apnées obstruc- tives du sommeil, hypertension artérielle et artère. La Presse Médicale, 38, 627-632.
 Tamisier, R., Richard, P., Sapene, M., Stach, B., Leguillou, F., Grillet, Y., Baguet, J.-P., Muir, J.-F. and Pepin, J.-L. (2015) L’hypertension artérielle est sous-diagnos- tiquée et/ou mal controlée chez les syndromes d’apnées obstructives du sommeil nouvellement diagnostiqués. Médecine du Sommeil, 12, 10-11.
 Salmina, D., Ogna, A., Wuerzner, G., Heinzer, R. and Ogna, V.F. (2019) Hypertension artérielle et syndrome des apnées obstructives du sommeil: Etat des connaissances. Revue Médicale Suisse, 15, 1620-1624.
 Adjoh, K.S., Adambounou, A.S., Gbadamassi, A.G., Efalou, P., Ouedraogo, A.R., Aziagbe, K.A., et al. (2017) Obstructive Sleep Apnea Syndrome: Epidemiological, Clinical and Paraclinical Aspects of the First Cases in Lome. Journal of Functional Ventilation and Pulmonology, 24, 10-17.
 Courreges, J.P., Aspar, J.Y., Cosma, V., Thuan, J.F., Vigier-Simorre, N. and Aboud, E. (2009) Interrelation hypertension artérielle résistante et syndrome d’apnée du sommeil chez le diabétique de type 2. Diabetes and Metabolism, 35, 34-35.
 Tietjens, J.R., Claman, D., Kezirian, E.J., De Marco, T., Mirzayan, A., Sadroonri, B., Goldberg, A.N., Long, C., Gerstenfeld, E.P. and Yeghiazarians, Y. (2019) Obstruc- tive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy. JAMA, 8, 1-17.